Fundz

Watching ARCUTIS BIOTHERAPEUTICS, INC.? See every signal: funding, hires, M&A, contracts, sentiment.

Book a demoChoose your plan
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

ARCUTIS BIOTHERAPEUTICS, INC.

http://www.arcutis.com/
Filed: Jul 15, 2026Westlake Village, CaliforniaCIK: 0001787306Health Care
Full company profileView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Arcutis Biotherapeutics appointed Christopher Peetz as a new independent Class III director on July 15, 2026, expanding the board from nine to ten members. This board expansion strengthens governance oversight as the company continues to grow.

Key Takeaways

Christopher Peetz appointed as new Class III director, increasing board size from 9 to 10 members

Mr. Peetz confirmed as an independent director, enhancing board independence and governance compliance

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJul 15, 2026
Item5.02
CategoryExecutive Change
CIK0001787306
Accession #arqt-20260715
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
board change

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

ARCUTIS BIOTHERAPEUTICS, INC. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.